See more : Yandex N.V. (YNDX.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Regen BioPharma, Inc. (RGBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Regen BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shunten International (Holdings) Limited (0932.HK) Income Statement Analysis – Financial Results
- Automotive Axles Limited (AUTOAXLES.NS) Income Statement Analysis – Financial Results
- Acumen Pharmaceuticals, Inc. (ABOS) Income Statement Analysis – Financial Results
- Tinka Resources Limited (TKRFF) Income Statement Analysis – Financial Results
- Bonso Electronics International Inc. (BNSOF) Income Statement Analysis – Financial Results
Regen BioPharma, Inc. (RGBP)
About Regen BioPharma, Inc.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.56K | 236.56K | 235.52K | 171.19K | 110.00K | 110.00K | 100.00K | 110.00K | 100.00K | 192.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 77.22K | 0.00 | 50.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 159.35K | 236.56K | 185.52K | 146.19K | 110.00K | 110.00K | 100.00K | 110.00K | 100.00K | 192.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 67.36% | 100.00% | 78.77% | 85.40% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 153.69K | 212.30K | 275.39K | 36.70K | 13.29K | 45.61K | 374.44K | 1.15M | 671.10K | 282.30K | 23.87K | 8.39K | 42.52K |
| General & Administrative | 423.85K | 651.21K | 299.73K | 335.26K | 306.03K | 821.18K | 1.15M | 1.47M | 2.39M | 1.89M | 682.49K | 311.44K | 358.74K |
| Selling & Marketing | 0.00 | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 423.85K | 711.21K | 299.73K | 335.26K | 306.03K | 821.18K | 1.15M | 1.47M | 2.39M | 1.89M | 682.49K | 311.44K | 358.74K |
| Other Expenses | 0.00 | 1.00 | 62.70K | 1.00 | 0.00 | 1.73K | -270.20K | 53.87K | -4.75M | 1.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 577.53K | 923.51K | 575.12K | 371.96K | 319.32K | 866.79K | 1.53M | 2.62M | 3.06M | 2.17M | 706.35K | 319.84K | 401.26K |
| Cost & Expenses | 654.75K | 923.51K | 575.12K | 371.96K | 319.32K | 866.79K | 1.53M | 2.62M | 3.06M | 2.17M | 706.35K | 319.84K | 401.26K |
| Interest Income | 0.00 | 0.00 | 455.00 | 230.00 | 942.93K | 1.30K | 10.23K | 1.86K | 1.20K | 1.15K | 233.00 | 0.00 | 0.00 |
| Interest Expense | -72.45K | 309.45K | 209.79K | 367.03K | 942.93K | 1.70M | 1.56M | 591.06K | 46.42K | 21.69K | 2.21K | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 1.90M | 339.61K | 200.77K | 209.32K | 874.91K | 1.43M | 2.53M | 2.96M | 1.15K | 233.00 | 319.84K | 401.26K |
| EBITDA | -418.19K | 1.22M | 2.99M | -6.40M | 4.36M | -753.75K | -3.15M | -2.46M | 0.00 | -2.19M | -706.12K | -35.20K | 234.07K |
| EBITDA Ratio | -176.78% | 514.02% | -136.70% | -117.14% | -190.29% | -685.23% | -1,685.75% | -2,231.96% | -7,704.17% | -1,030.28% | 0.00% | 0.00% | 0.00% |
| Operating Income | -418.19K | -686.95K | -339.61K | -200.77K | -209.32K | -756.79K | -1.43M | -2.51M | -2.96M | -1.98M | -706.35K | -319.84K | -401.26K |
| Operating Income Ratio | -176.78% | -290.39% | -144.20% | -117.28% | -190.29% | -687.99% | -1,425.78% | -2,282.62% | -2,956.96% | -1,030.87% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -449.06K | 1.84M | 2.78M | -6.56M | 3.62M | -1.87M | -3.29M | -3.33M | -456.56K | -231.44K | -50.00K | -35.20K | 0.00 |
| Income Before Tax | -867.25K | 1.16M | 2.44M | -6.77M | 3.41M | -2.62M | -4.72M | -5.84M | -7.75M | -11.20M | -756.35K | -355.03K | -401.26K |
| Income Before Tax Ratio | -366.61% | 488.89% | 1,037.52% | -3,951.79% | 3,104.02% | -2,384.71% | -4,715.20% | -5,308.22% | -7,750.59% | -5,830.81% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | -3.05M | 366.80K | 1.63M | 1.70M | 3.02M | 589.21K | 45.22K | 20.54K | 1.98K | -319.84K | 0.00 |
| Net Income | -867.25K | 1.02M | 5.49M | -7.13M | 1.79M | -4.32M | -4.72M | -5.84M | -7.75M | -11.20M | -756.35K | -355.03K | -401.26K |
| Net Income Ratio | -366.61% | 432.66% | 2,330.99% | -4,166.05% | 1,626.00% | -3,931.03% | -4,715.20% | -5,308.22% | -7,750.59% | -5,830.81% | 0.00% | 0.00% | 0.00% |
| EPS | -0.21 | 0.29 | 1.75 | -3.55 | 1.90 | -3.13 | -46.50 | -61.93 | -90.94 | -190.43 | -21.93 | -28.10 | 0.00 |
| EPS Diluted | -0.21 | 0.29 | 1.75 | -3.55 | 1.90 | -3.13 | -46.50 | -61.93 | -90.94 | -190.43 | -21.93 | -28.10 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 3.54M | 3.14M | 2.01M | 939.90K | 1.38M | 101.39K | 94.28K | 85.23K | 58.79K | 34.49K | 12.63K | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 3.54M | 3.14M | 2.01M | 939.90K | 1.38M | 101.39K | 94.28K | 85.23K | 58.79K | 34.49K | 12.63K | 0.00 |
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO , Jan. 23, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and...
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time interactive presentation at the Emerging Growth Conference. SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and...
Source: https://incomestatements.info
Category: Stock Reports